FDA approves Bracco’s READI-CAT 2 and READI-CAT 2 SMOOTHIE for use in abdominal CT.
The U.S. Food and Drug Administration has approved a New Drug Application for READI-CAT 2 and READI-CAT 2 SMOOTHIE, barium sulfate oral suspensions for use in CT.
READI-CAT 2 and READI-CAT 2 SMOOTHIE, products of Bracco Imaging, a subsidiary of Bracco Diagnostics, are used in CT of the abdomen to delineate the gastrointestinal tract in adult and pediatric patients, a release said.
This approval is the second regulatory approval of a barium-based contrast agent in the U.S., and the first for use in modern CT imaging, Bracco’s release said.
READI-CAT 2 is supplied in 450 mL bottles; READI-CAT 2 SMOOTHIES, also in 450 mL bottles, are available for use by adult and pediatric patients in berry, banana, creamy vanilla and mochaccino flavors.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.